These limitations highlight the need for new approaches and novel targets, including hormone-sparing treatments and non-AR targeted therapies, to better address the varied clinical needs of patients with prostate cancer, particularly those with advanced prostate cancer or mCRPC. Here, AR is linked to Familial prostate cancer.